Editorial Material
Hematology
Heinz Zoller, Sonja Wagner, Benedikt Schaefer
Summary: This study found that hypophosphataemia is a common side-effect in patients with iron deficiency anaemia treated with ferric carboxymaltose, and it may even require intravenous supplementation of phosphate with unknown long-term consequences.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Saki Tahara, Yoshiro Naito, Keisuke Okuno, Seiki Yasumura, Tetsuo Horimatsu, Junichi Ohno, Isamu Sunayama, Yuki Matsumoto, Eri Manabe, Kumiko Masai, Kohei Azuma, Koichi Nishimura, Kyung-Duk Min, Akiko Goda, Masanori Asakura, Masaharu Ishihara
Summary: Anemia and iron deficiency are common in patients with heart failure, and IV administration of iron improves outcomes in patients with decompensated heart failure and iron deficiency. The current diagnostic methods for iron deficiency have limitations, and alternative methods should be considered. Reticulocyte hemoglobin equivalent (Ret-He) is a potential indicator for iron content, but its clinical utility in patients with heart failure remains uncertain. Further investigation is needed to determine the clinical usefulness of Ret-He in identifying iron deficiency, predicting response to IV iron, and prognosis in patients with heart failure.
SCIENTIFIC REPORTS
(2022)
Review
Medicine, Research & Experimental
John A. Glaspy, Myles Wolf, William E. Strauss
Summary: Some intravenous iron formulations can lead to severe hypophosphatemia, especially in patients treated with ferric carboxymaltose. The consequences of severe HPP are usually bone abnormalities. However, there are still uncertainties and limitations in the research on HPP.
ADVANCES IN THERAPY
(2021)
Article
Gastroenterology & Hepatology
Trond Espen Detlie, Jonas Christoffer Lindstrom, Marte Eide Jahnsen, Elisabeth Finnes, Heinz Zoller, Bjorn Moum, Jorgen Jahnsen
Summary: High-dose intravenous iron is an effective treatment option for iron deficiency in IBD, but treatment with FCM has been associated with the development of hypophosphatemia. This study found that FCM-treated patients had significantly higher fibroblast growth factor 23 levels and decreased vitamin D and calcium levels compared to patients who received FDI, but no significant short-term clinical impact of hypophosphatemia was demonstrated.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Clinical Neurology
Hyoeun Bae, Yong Won Cho, Keun Tae Kim, Richard P. Allen, Christopher J. Earley
Summary: This study demonstrates the significant efficacy and safety of FCM 1500mg treatment in both short-term (6 weeks) and long-term (52 weeks) outcomes for RLS patients with IDA. It also shows a significant improvement in sleep quality and a high proportion (61%) of subjects no longer needing RLS medications at the end of the Phase II.
Article
Medicine, General & Internal
Roberto Minutolo, Patrizia Berto, Maria Elena Liberti, Nicola Peruzzu, Silvio Borrelli, Antonella Netti, Carlo Garofalo, Giuseppe Conte, Luca De Nicola, Lucia Del Vecchio, Francesco Locatelli
Summary: In non-hemodialysis CKD patients, ferric carboxymaltose (FCM) effectively corrects iron-deficient anemia and allows remarkable cost savings from societal, healthcare, and patient perspectives.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Jie Jin, Zhihua Ran, Emanuele Noseda, Bernard Roubert, Matthieu Marty, Anna Mezzacasa, Udo Michael Goring
Summary: Ferric carboxymaltose (FCM) and iron sucrose (IS) have similar effects in treating iron deficiency anemia (IDA), but FCM shows a faster hemoglobin response and correction of iron deficiency.
FRONTIERS OF MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Lucia Cococcioni, Licia Pensabene, Sara El-Khouly, Sibongile Chadokufa, Sara McCartney, Efstratios Saliakellis, Fevronia Kiparissi, Osvaldo Borrelli
Summary: The study assessed the efficacy of intravenous ferric carboxymaltose (FCM) in treating iron deficiency anemia (IDA) in children with inflammatory bowel disease (IBD) and found that FCM administration is effective in managing IDA in pIBD, including children under 6 years of age. However, post-infusion hypophosphatemia was common and serum phosphate monitoring should be mandatory to prevent severe cases.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Medicine, Research & Experimental
Seiji Fukumoto, Tatsunori Murata, Yutaka Osuga, Richard F. Pollock
Summary: This study compared two iron formulations in patients with iron deficiency anemia and found that patients treated with FDI had a lower incidence of hypophosphatemia.
ADVANCES IN THERAPY
(2023)
Review
Medicine, General & Internal
Hye Won Shin, Doo Yeon Go, Suk Woo Lee, Yoon Ji Choi, Eun Ji Ko, Hae Sun You, Yoo Kyung Jang
Summary: This systematic review compared the efficacy and safety of ferric carboxymaltose (FCM) and iron sucrose (IS) in treating iron deficiency anemia (IDA) in obstetric and gynecologic patients. The results showed that FCM was more effective in increasing Hb and ferritin levels compared to IS, with a more favorable safety profile.
Article
Medicine, General & Internal
Hyo-Hyun Kim, Eun Hye Park, Seung Hyun Lee, Kyung-Jong Yoo, Young-Nam Youn
Summary: Patients with iron deficiency anemia (IDA) who were scheduled for off-pump coronary artery bypass grafting (OPCAB) were randomly assigned to receive either intravenous ferric carboxymaltose (IVFC) or placebo treatment. The IVFC treatment significantly reduced the need for red blood cell and platelet transfusions, and patients in the IVFC group had higher levels of hematologic parameters and iron concentrations after surgery. Preoperative IVFC treatment improved the values of hematologic parameters and iron bioavailability in patients with IDA undergoing OPCAB.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Burak Yasin Aktas, Emine Busra Ata, Engin Cesmeci, Ibrahim Yahya Cakir, Muharrem Coskunpinar, Yagmur Tahillioglu, Gurkan Guner, Deniz Can Guven, Zafer Arik, Neyran Kertmen, Omer Dizdar, Suayib Yalcin, Sercan Aksoy
Summary: Iron carboxymaltose treatment is an effective and safe alternative for cancer patients with iron-deficiency anemia, showing significant improvement in hemoglobin levels and favorable outcomes across different tumor types.
Article
Pediatrics
Patricia Garcia-Ortega, Ines Jimenez-Lozano, Alejandro Cruz, Aurora Fernandez Polo, Mercedes Lopez, Gema Ariceta
Summary: This study retrospectively evaluated the safety and effectiveness of FCM treatment in pediatric patients with CKD non-dependent of hemodialysis. The results showed that FCM can improve anemia and is well-tolerated in pediatric patients with CKD, with a low incidence of adverse effects.
FRONTIERS IN PEDIATRICS
(2022)
Review
Pharmacology & Pharmacy
Irina Blumenstein, Satish Shanbhag, Peter Langguth, Philip A. Kalra, Heinz Zoller, Wendy Lim
Summary: The newest intravenous iron products have shown improved safety profiles, but immediate infusion reactions and the development of hypophosphatemia must still be recognized. Proper recognition and management of infusion reactions is crucial for successful IV iron administration.
EXPERT OPINION ON DRUG SAFETY
(2021)
Letter
Medicine, General & Internal
Natalia Scaramellini, Marco Capecchi, Andrea Artoni, Silvia La Marca, Maria Domenica Cappellini, Irene Motta
Summary: Inherited platelet function defects lead to sub-acute and chronic bleedings, oral iron supplementation for iron deficiency anemia may be insufficient, and intravenous iron is used for severe anemia or GI intolerance. Currently available iron compounds allow high-dose administration with low immunogenicity, though there is limited research on their effectiveness in patients with inherited platelet disorders.
INTERNAL AND EMERGENCY MEDICINE
(2021)
Article
Endocrinology & Metabolism
Erik A. Imel, Xiaoping Zhang, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey S. Humphrey, Francis H. Glorieux, Anthony A. Portale, Karl Insogna, Munro Peacock, Thomas O. Carpenter
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2015)
Article
Pharmacology & Pharmacy
Xiaoping Zhang, Erik A. Imei, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey Humphrey, Francis H. Glorieux, Anthony A. Portale, Karl Insogna, Thomas O. Carpenter, Munro Peacock
JOURNAL OF CLINICAL PHARMACOLOGY
(2016)
Editorial Material
Medicine, Research & Experimental
Thomas J. Weber
JOURNAL OF CLINICAL INVESTIGATION
(2016)
Article
Endocrinology & Metabolism
Thomas J. Weber, Eileen K. Sawyer, Scott Moseley, Tatjana Odrljin, Priya S. Kishnani
METABOLISM-CLINICAL AND EXPERIMENTAL
(2016)
Article
Endocrinology & Metabolism
Thomas J. Weber, James Koh, Samantha M. Thomas, Joyce A. Hogue, Randall P. Scheri, Sanziana A. Roman, Julie A. Sosa
METABOLISM-CLINICAL AND EXPERIMENTAL
(2017)
Article
Endocrinology & Metabolism
Karl L. Insogna, Karine Briot, Erik A. Imel, Peter Kamenicky, Mary D. Ruppe, Anthony A. Portale, Thomas Weber, Pisit Pitukcheewanont, Hae Il Cheong, Suzanne Jan de Beur, Yasuo Imanishi, Nobuaki Ito, Robin H. Lachmann, Hiroyuki Tanaka, Farzana Perwad, Lin Zhang, Chao-Yin Chen, Christina Theodore-Oklota, Matt Mealiffe, Javier San Martin, Thomas O. Carpenter
JOURNAL OF BONE AND MINERAL RESEARCH
(2018)
Article
Medicine, Research & Experimental
Thomas O. Carpenter, Erik A. Imel, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Margaret M. Wooddell, Tetsuyoshi Kawakami, Takahiro Ito, Xiaoping Zhang, Jeffrey Humphrey, Karl L. Insogna, Munro Peacock
JOURNAL OF CLINICAL INVESTIGATION
(2014)
Article
Geriatrics & Gerontology
Annalise N. Pham, Santanu K. Datta, Thomas J. Weber, Louise C. Walter, Cathleen S. Colon-Emeric
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2011)
Article
Geriatrics & Gerontology
Richard H. Lee, Thomas Weber, Cathleen Colon-Emeric
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2013)
Editorial Material
Surgery
Dawn M. Elfenbein, Thomas J. Weber, Randall P. Scheri
Article
Immunology
Julie J. Kim-Chang, Lorena Wilson, Cliburn Chan, Bernard Fischer, Guglielmo Venturi, Maureen M. Goodenow, Grace Aldrovandi, Thomas J. Weber, John W. Sleasman
AIDS RESEARCH AND HUMAN RETROVIRUSES
(2019)
Article
Endocrinology & Metabolism
Anthony A. Portale, Thomas O. Carpenter, Maria Luisa Brandi, Karine Briot, Hae Il Cheongs, Martine Cohen-Solal, Rachel Crowley, Suzanne Jan De Beur, Richard Eastell, Yasuo Imanishi, Erik A. Imel, Steven Ing, Nobuaki Ito, Muhammad Javaid, Peter Kamenicky, Richard Keen, Takuo Kubota, Robin Lachmann, Farzana Perwad, Pisit Pitukcheewanont, Stuart H. Ralston, Yasuhiro Takeuchi, Hiroyuki Tanaka, Thomas J. Weber, Han-Wook Yoo, Lin Zhang, Christina Theodore-Oklota, Matt Mealiffe, Javier San Martin, Karl Insogna
CALCIFIED TISSUE INTERNATIONAL
(2019)
Article
Endocrinology & Metabolism
Suzanne M. Jan de Beur, Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl Insogna, Rajiv Kumar, Frank Rauch, Diana Luca, Tricia Cimms, Mary Scott Roberts, Javier San Martin, Thomas O. Carpenter
Summary: The study demonstrated that burosumab exhibited an acceptable safety profile in adult patients with TIO and was associated with improvements in phosphate metabolism and osteomalacia.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Gerontology
Samantha L. Solimeo, Thomas J. Weber, Deborah T. Gold